Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA

Watchlist Manager
Kiniksa Pharmaceuticals Ltd Logo
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Watchlist
Price: 42.11 USD -0.78% Market Closed
Market Cap: $3.2B

Operating Margin

6.4%
Current
Improving
by 8.2%
vs 3-y average of -1.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
6.4%
=
Operating Income
$38.2m
/
Revenue
$598m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
6.4%
=
Operating Income
$38.2m
/
Revenue
$598m

Peer Comparison

Country Company Market Cap Operating
Margin
BM
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
3.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Bermuda
Percentile
49th
Based on 195 companies
49th percentile
6.4%
Low
-73 643.6% — 2.6%
Typical Range
2.6% — 19.1%
High
19.1% — 68.5%
Distribution Statistics
Bermuda
Min -73 643.6%
30th Percentile 2.6%
Median 6.8%
70th Percentile 19.1%
Max 68.5%

Kiniksa Pharmaceuticals Ltd
Glance View

Market Cap
3.2B USD
Industry
Biotechnology

Founded with a vision to tackle some of the most challenging inflammatory and autoimmune diseases, Kiniksa Pharmaceuticals Ltd. emerged as a nimble player in the competitive biotechnology landscape. This company, leveraging the vast potential of advanced scientific knowledge and biotechnological breakthroughs, focuses on developing and commercializing innovative therapies. Its portfolio is strategically designed to address unmet needs in the treatment of debilitating diseases. Central to its operations is a robust pipeline of monoclonal antibodies and cutting-edge biologics that promise new hope for patients. Guided by a commitment to rigorous clinical development and strategic collaborations, Kiniksa seeks to navigate the complexities of regulatory pathways, bringing its specialized therapeutic solutions to global markets. The financial engine of Kiniksa's ambitious journey is fueled by a combination of strategic partnerships, successful licensing agreements, and prudent capital allocation. By forging alliances with larger pharmaceutical firms, the company gains access to invaluable resources and distribution channels while minimizing its financial risks. This collaborative approach not only expedites the development process but also amplifies market reach, ensuring that novel treatments are accessible to the patients who need them. Revenue streams are bolstered through a mix of upfront payments, milestone achievements, and royalties as its therapies progress through stages of clinical trials and, finally, into the hands of healthcare providers. This business model, one that intertwines innovation with strategic alliances, is designed to sustain growth, balance risk, and ultimately fulfill the company's mission of transforming patients’ lives.

KNSA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
6.4%
=
Operating Income
$38.2m
/
Revenue
$598m
What is Kiniksa Pharmaceuticals Ltd's current Operating Margin?

The current Operating Margin for Kiniksa Pharmaceuticals Ltd is 6.4%, which is above its 3-year median of -1.8%.

How has Operating Margin changed over time?

Over the last 3 years, Kiniksa Pharmaceuticals Ltd’s Operating Margin has increased from -18.3% to 6.4%. During this period, it reached a low of -18.3% on Aug 30, 2022 and a high of 13.6% on Jun 30, 2023.

Back to Top